Petvivo Holdings, Inc. (PETV) Stock Price & Analysis

Petvivo Holdings, Inc. (PETV) rose 0.00% to USD 0.8 as of June 10, 2026 at 07:40 UTC, according to Nexqual real-time market data.

PETV last closed at USD 0.8; the session ranged USD 0.75–0.8 on volume of 1,500 shares. Market capitalization is $29.16M, with a 52-week range of USD 0.6–1.69 (OQX). Source: Nexqual, June 10, 2026 at 07:40 UTC.

Key Statistics (as of June 10, 2026 at 07:40 UTC)

Technical Analysis (PETV)

Nexqual's technical model rates PETV "BUY" based on 4 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 07:40 UTC.

Analyst Ratings (PETV)

Wall Street analysts rate PETV "None", per Nexqual as of June 10, 2026 at 07:40 UTC.

Earnings (PETV)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 07:40 UTC.

Financials & Fundamentals (PETV)

Source: Nexqual, June 10, 2026 at 07:40 UTC.

Financial Health Score (PETV)

Nexqual rates Petvivo Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:40 UTC.

Ownership (PETV)

Source: Nexqual, June 10, 2026 at 07:40 UTC.

Leadership (PETV)

Petvivo Holdings, Inc. is led by John Lai (age 63), CEO, President & Director, per Nexqual as of June 10, 2026 at 07:40 UTC.

Major Backers & Investors (PETV)

Notable institutional backers of Petvivo Holdings, Inc. include Vermillion Wealth Management, Inc. , according to Nexqual as of June 10, 2026 at 07:40 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 07:40 UTC.

From Petvivo Holdings, Inc.'s Latest SEC 10-K Filing (filed 2025-07-10)

Key Strengths & Strategy (as disclosed to the SEC)

• In addition, the FDA and other U.S. regulatory bodies (including the Federal Trade Commission, the Office of the Inspector General of the Department of Health and Human Services, the Department of Justice (DOJ), and various state Attorneys General) monitor the manner in which we promote and advertise our products.
• In addition to the United States patent portfolio, we also have four patents granted in key markets around the world including Canada and countries within the European Union.   We believe we have developed a broad and deep patent portfolio around our biomaterials and manufacturing processes in addition to the application of these biomaterials for use as medical devices, medical device coatings, and pharmaceutical delivery devices.
• We believe our intellectual property portfolio strongly protects our proprietary technology, including the composition of raw elements used to produce our formulations, the fabricated biomaterials, and their application in end products, thereby making our material and devices much more attractive to industry partners.   Furthermore, we rely on proprietary trade secrets and confidential know-how to protect various aspects of its product formulations and manufacturing processes.
• We also strenuously protect our proprietary information and proprietary technology through a combination of contractual arrangements, trade secrets, and patents, both in the United States and abroad.

Partnerships

• In December 2023, the Company entered into a non-exclusive distribution agreement with Covetrus North America, LLC ("Covetrus Distribution Agreement"), to market, distribute and sell the Company's products in the United States, including the District of Colombia.
• In March 2025, we mutually terminated our non-exclusive distribution agreement with MWI.   We entered into a Distribution Services Agreement (the "Agreement") with Covetrus on December 18, 2023.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:40 UTC. This page is informational and not investment advice.